Peter G. Linde

2.1k total citations · 1 hit paper
25 papers, 828 citations indexed

About

Peter G. Linde is a scholar working on Hematology, Genetics and Nephrology. According to data from OpenAlex, Peter G. Linde has authored 25 papers receiving a total of 828 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 9 papers in Genetics and 6 papers in Nephrology. Recurrent topics in Peter G. Linde's work include Hemoglobinopathies and Related Disorders (6 papers), Acute Myeloid Leukemia Research (4 papers) and Erythrocyte Function and Pathophysiology (4 papers). Peter G. Linde is often cited by papers focused on Hemoglobinopathies and Related Disorders (6 papers), Acute Myeloid Leukemia Research (4 papers) and Erythrocyte Function and Pathophysiology (4 papers). Peter G. Linde collaborates with scholars based in United States, United Kingdom and France. Peter G. Linde's co-authors include Colin J. Meyer, Melanie Chin, George L. Bakris, Peter A. McCullough, Vallerie V. McLaughlin, Ioana R. Preston, Pilar Escribano Subías, Aaron B. Waxman, Solaiappan Manimaran and G. Meyer and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Peter G. Linde

25 papers receiving 808 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sotatercept for the Treatment of Pulmonary Arterial Hypertension

2021 322 citations Peter G. Linde et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter G. Linde United States	10	316	262	240	152	101	25	828
Yuya Horinouchi Japan	19	231 0.7×	250 1.0×	79 0.3×	97 0.6×	112 1.1×	42	890
Margarita Angerosa Argentina	19	147 0.5×	137 0.5×	98 0.4×	168 1.1×	196 1.9×	42	840
Eric E. Simon United States	17	102 0.3×	391 1.5×	95 0.4×	419 2.8×	63 0.6×	49	1.1k
Yuet‐Ching Tay Australia	16	106 0.3×	344 1.3×	110 0.5×	668 4.4×	83 0.8×	25	1.2k
Elena Burillo Spain	19	243 0.8×	279 1.1×	263 1.1×	34 0.2×	74 0.7×	31	1.1k
William A. Wilmer United States	15	126 0.4×	365 1.4×	181 0.8×	559 3.7×	41 0.4×	20	1.2k
Marisa Cañadas‐Garre Spain	19	175 0.6×	435 1.7×	39 0.2×	76 0.5×	51 0.5×	44	1.0k
M. Eugenia Burgos Chile	15	98 0.3×	414 1.6×	158 0.7×	474 3.1×	39 0.4×	24	1.1k
Yu-Juei Hsu Taiwan	12	193 0.6×	363 1.4×	137 0.6×	90 0.6×	17 0.2×	20	864
Brian A. Moser United States	14	105 0.3×	195 0.7×	419 1.7×	111 0.7×	30 0.3×	24	935

Countries citing papers authored by Peter G. Linde

Since Specialization

Citations

This map shows the geographic impact of Peter G. Linde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter G. Linde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter G. Linde more than expected).

Fields of papers citing papers by Peter G. Linde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter G. Linde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter G. Linde. The network helps show where Peter G. Linde may publish in the future.

Co-authorship network of co-authors of Peter G. Linde

This figure shows the co-authorship network connecting the top 25 collaborators of Peter G. Linde. A scholar is included among the top collaborators of Peter G. Linde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter G. Linde. Peter G. Linde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ray, Adrian S., Dan Cui, Gillian Bain, et al.. (2021). P306 MORF-057, an oral selective α4β7 integrin inhibitor for Inflammatory Bowel Disease, leads to specific target engagement in a single and multiple ascending dose study in healthy subjects. Journal of Crohn s and Colitis. 15(Supplement_1). S333–S335. 4 indexed citations

Chen, Nianhang, Nastya Kassir, Abderrahmane Laadem, et al.. (2020). Population Pharmacokinetics and Exposure–Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes. CPT Pharmacometrics & Systems Pharmacology. 9(7). 395–404. 6 indexed citations

Komrokji, Rami S., Mikkael A. Sekeres, Amer M. Zeidan, et al.. (2020). Longer-term RBC transfusion reduction in the phase III MEDALIST study of luspatercept in patients (pts) with lower-risk MDS with ring sideroblasts (RS).. Journal of Clinical Oncology. 38(15_suppl). 7518–7518. 1 indexed citations

Porter, John B., Maria Domenica Cappellini, Thomas D. Coates, et al.. (2019). Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial. Blood. 134(Supplement_1). 2245–2245. 8 indexed citations

Viprakasit, Vip, Alì Taher, Olivier Hermine, et al.. (2019). Evaluating Luspatercept Responders in the Phase 3, Randomized, Double-Blind, Placebo-Controlled BELIEVE Trial of Luspatercept in Adult Beta-Thalassemia Patients (Pts) Who Require Regular Red Blood Cell (RBC) Transfusions. Blood. 134(Supplement_1). 3545–3545. 2 indexed citations

Garcia‐Manero, Guillermo, Ghulam J. Mufti, Pierre Fenaux, et al.. (2019). Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. Blood. 134(Supplement_1). 4243–4243. 11 indexed citations

Mesa, Ruben A., Giovanni Barosi, Claire Harrison, et al.. (2018). A phase 2, multicenter, open-label study of the safety and efficacy of luspatercept in subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia with or without RBC transfusion dependence.. Journal of Clinical Oncology. 36(15_suppl). TPS7083–TPS7083. 4 indexed citations

Webb, Nicholas J.A., Gary Lerner, Bradley A. Warady, et al.. (2017). Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease. Pediatric Nephrology. 32(7). 1221–1232. 7 indexed citations

Platzbecker, Uwe, Ulrich Germing, Philipp Kiewe, et al.. (2017). Luspatercept Response in New Subpopulations of Patients with Lower-Risk Myelodysplastic Syndromes (MDS): Update of the Pace Study. Leukemia Research. 55. S31–S31. 1 indexed citations

10.

Linde, Peter G., Patrick Archdeacon, Matthew D. Breyer, et al.. (2016). Overcoming Barriers in Kidney Health—Forging a Platform for Innovation. Journal of the American Society of Nephrology. 27(7). 1902–1910. 23 indexed citations

11.

Chin, Melanie, George L. Bakris, Glenn M. Chertow, et al.. (2014). Risk Factors for Heart Failure in Patients With Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated With Bardoxolone Methyl. Journal of Cardiac Failure. 20(12). 953–958. 130 indexed citations

12.

Chin, Melanie, Scott A. Reisman, George L. Bakris, et al.. (2014). Mechanisms Contributing to Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated with Bardoxolone Methyl. American Journal of Nephrology. 39(6). 499–508. 125 indexed citations

13.

Akizawa, Tadao, Takashi Akiba, Hideki Hirakata, et al.. (2014). Comparison of Paricalcitol With Maxacalcitol Injection in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism. Therapeutic Apheresis and Dialysis. 19(3). 225–234. 13 indexed citations

14.

Heerspink, Hiddo J.L., Glenn M. Chertow, Tadao Akizawa, et al.. (2013). Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrology Dialysis Transplantation. 28(11). 2841–2850. 20 indexed citations

15.

Jönsson, Anders, Mika Lehto, Henrik Ahn, et al.. (2012). Microwave Ablation in Mitral Valve Surgery for Atrial Fibrillation (MAMA).. PubMed. 5(2). 432–432. 9 indexed citations

16.

Almroth, Henrik, Tommy Andersson, Espen Fengsrud, et al.. (2011). The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events. Journal of Internal Medicine. 270(3). 281–290. 27 indexed citations

17.

Provenzano, Robert, James A. Tumlin, Raja I. Zabaneh, et al.. (2011). 254 Pharmacokinetics of Oral FG-4592 to Treat Anemia in Hemodialysis (HD) Patients (PTS). American Journal of Kidney Diseases. 57(4). B80–B80. 2 indexed citations

18.

Ahlsson, Anders, Peter G. Linde, Peter Rask, & Anders Englund. (2008). Atrial function after epicardial microwave ablation in patients with atrial fibrillation. Scandinavian Cardiovascular Journal. 42(3). 192–201. 7 indexed citations

19.

Mehra, Mandeep R., Mark L. Barr, Robert C. Bourge, et al.. (2007). Rationale, design, and methods for the Transplant-Eligible MAnagement of Congestive Heart Failure (TMAC) trial: A multicenter clinical outcomes trial using nesiritide for TMAC. American Heart Journal. 153(6). 932–940. 3 indexed citations

20.

Linde, Peter G., et al.. (1990). [Meteorologic effects on hemorrhagic diathesis in hemophilia. 2. Weather effects on hemophilia with special reference to the atmospheric temperature-humidity complex].. PubMed. 45(21). 659–62. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact